Jpmorgan Chase & CO Cassava Sciences Inc Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SAVA
# of Institutions
188Shares Held
13.5MCall Options Held
1.42MPut Options Held
2.05M-
Black Rock Inc. New York, NY3.22MShares$83.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.68MShares$69.3 Million0.0% of portfolio
-
State Street Corp Boston, MA1.18MShares$30.4 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA967KShares$25 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA691KShares$17.9 Million0.0% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $1.04B
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...